tumor growth News
-
Alpha-1 Biologics Announces Positive Data Published in frontiers in Oncology on Alphataxin in Combination with Anti-PD-1 Therapy that Suppressed Murine Renal Cancer and Metastasis
Alpha-1 Biologics, a biotherapeutics company developing innovative treatments for cancers and immune deficiencies, today announced that positive data was published in frontiers in Oncology demonstrating Alphataxin, a small molecule that elevates circulating and tumor-infiltrating CD4+ T cells, suppressed kidney cancer and suppressed metastasis in mice. Orally available Alphataxin, is the first ...
-
Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors
Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). “There is a high unmet medical ...
By Camurus AB
-
Filtricine Preclinical Results Published
Filtricine is pleased to announce that the preclinical research results of its proprietary medical food technology, Targeted Nutrients Deprivation (TND), have been published in Nutrition and Cancer. “Broad Anti-Cancer Activity Produced by Targeted Nutrients Deprivation (TND) of Multiple Non-Essential Amino Acids” Filtricine’s core medical food technology is the ...
-
Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity
PAD4 inhibition a novel pathway to inhibit tumor metastasis and tumor growth Data presented at the American Association of Cancer Research Annual Meeting 2022 Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced data to be presented at the American ...
-
Arsenic turns stem cells cancerous, spurring tumor growth
Researchers at the National Institutes of Health have discovered how exposure to arsenic can turn normal stem cells into cancer stem cells and spur tumor growth. Inorganic arsenic, which affects the drinking water of millions of people worldwide, has been previously shown to be a human carcinogen. A growing body of evidence suggests that cancer is a stem-cell based disease. Normal stem cells are ...
-
The Wistar Institute and Jubilant Therapeutics Inc. Find PAD4 Inhibition in Neutrophils, Halts Cancer Progression and Metastasis
Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at the Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor ...
-
BriaCell Secures License for a Promising Novel Anti-Cancer Agent
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the ...
-
Obesity Primes the Colon for Cancer, According to NIH Study
Obesity, rather than diet, causes changes in the colon that may lead to colorectal cancer, according to a study in mice by the National Institutes of Health. The finding bolsters the recommendation that calorie control and frequent exercise are not only key to a healthy lifestyle, but a strategy to lower the risk for colon cancer, the second leading cause of cancer-related death in the United ...
-
NIEHS Funds Six Early-Career Researchers For Innovative Science
New grants totaling $3 million will go to six outstanding early-career scientists, bridging a funding gap to independent biomedical research. The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, created the award to encourage early stage researchers who want to discover how our environment influences human health. The highly competitive ...
-
Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi
Hydrogen peroxide isn’t just that bottled colorless liquid in the back of the medicine cabinet that’s used occasionally for cleaning scraped knees and cut fingers.It’s also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system’s first ...
-
Creative Proteomics Cytokine Boosts Cancer Research with Cancer Cytokines Assay
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company was pleased to announce the launch of its Cancer Cytokines Assay, assisting in the detection of multiple cytokine ...
-
Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ...
By Elpiscience
-
Emerging Trends in the BioPharma Industry that you Need to Know
Emerging trends in the biopharma industry include new developments in cancer treatments, advances in gene therapy, and more data-driven decision-making. As a leader in the sector, it’s important to be aware of these developments to make informed decisions about your organization’s direction. In this blog post, we’ll explore some of the most significant emerging trends in ...
By Brio Group
-
Agilent Technologies Thought Leader Award Supports Dr. Carolyn Mountford, University of Newcastle, Australia
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Carolyn Mountford has received an Agilent Thought Leader Award in recognition of her innovative work using nuclear magnetic resonance (NMR) spectroscopy technology in cancer research. Dr. Mountford is a professor of radiology at The University of Newcastle Australia School of Health Sciences, and Harvard Medical School. She is the ...
-
ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
-
ABOLOGIX awarded a two year Innosuisse Innovation
Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner and Abologix the implementation partner.The collaboration plans to study the mechanism of action involved in arresting tumour growth through the selective blocking of Junction Adhesion Molecule JAM-C by monoclonal antibodies supplied ...
By Abologix
-
Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is ...
-
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells HiT works as well, or better than, a TRuC construct targeting mesothelin in preclinical studies Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported preclinical data from its HiT targeting mesothelin, being ...
-
CD BioSciences Introduces mTOR Pathway for Metabolism Research
CD BioSciences, a US-based life science research product supplier and CRO, recently launches mTOR Pathway to the life science community for research applications. These new signaling pathways and other metabolic signaling pathways, such as Insulin Signaling Pathway and AMPK pathway, will support researchers in all aspects of cell death study. A metabolic pathway is a series of metabolic chemical ...
-
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen's QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you